Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUIBRON-T vs AMINOPHYLLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular c AMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.
Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
FDA-approved: Treatment of symptoms and prevention of asthma and reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD).,Off-label: Apnea of prematurity.,Off-label: Adjunctive therapy in chronic obstructive pulmonary disease (COPD).
Treatment of acute bronchial asthma, reversible bronchospasm associated with chronic bronchitis and emphysema,Neonatal apnea (off-label),Adjunctive therapy in COPD exacerbations
Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Terminal elimination half-life: 7-9 hours in nonsmoking adults; prolonged in hepatic cirrhosis (up to 30 hours) or heart failure; shorter in smokers (4-5 hours) due to enzyme induction.
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Primarily hepatic metabolism via cytochrome P450 enzymes, mainly CYP1A2, with minor contributions from CYP2E1 and CYP3A4.
Hepatic demethylation and oxidation via cytochrome P450 isoenzymes (CYP1A2, CYP3A4, CYP2E1); approximately 10% excreted unchanged in urine.
Renal: 70% as metabolites (1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid) and 10% as unchanged drug in adults; biliary/fecal: minimal, <5%.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Approximately 40% bound to plasma proteins, primarily albumin.
~40% bound to plasma proteins (primarily albumin).
0.5 L/kg (0.3-0.7 L/kg); approximates total body water, indicating distribution into body tissues including the central nervous system.
0.5 L/kg (range 0.3–0.7 L/kg); increased in neonates, cirrhosis, and malnutrition; reflects distribution into total body water.
Oral immediate-release: 96-100%; food may alter absorption rate of sustained-release (not extent).
Oral (immediate-release): 100% (well absorbed); rectal: ~80% (variable); IV: 100%.
GFR <10 m L/min: decrease dose by 50% and extend dosing interval to every 12-24 hours; monitor serum concentrations.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25% and monitor levels; GFR <10 m L/min: reduce dose by 50% and monitor levels closely.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: decrease dose by 50%; Child-Pugh Class C: decrease dose by 75% or consider alternative therapy.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: use with extreme caution, reduce dose by 90% or consider alternative.
Oral: 5 mg/kg every 6 hours for immediate-release; sustained-release not recommended for children <6 years; for ages 6-12: 10-20 mg/kg/day divided every 12 hours.
Loading dose: 5-6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: infants <1 year: 0.4-0.7 mg/kg/hr IV; children 1-9 years: 0.8-1.0 mg/kg/hr IV; children >9 years: 0.6-0.8 mg/kg/hr IV. Oral: immediate-release 5 mg/kg every 6 hours; sustained-release not recommended under 6 years.
Start at lowest effective dose (e.g., 200 mg every 12 hours) due to reduced clearance; monitor serum concentrations to avoid toxicity.
Reduce maintenance dose by 50-75% compared to younger adults; monitor serum theophylline levels closely; typical starting maintenance: 0.3-0.5 mg/kg/hr IV; avoid doses >400 mg/day oral.
None for Quibron-T specifically. However, theophylline products carry warnings about the potential for serious adverse effects including seizures and arrhythmias, especially at serum levels above 20 mcg/m L.
No specific FDA boxed warning for aminophylline; however, theophylline (its active metabolite) has a narrow therapeutic index and requires serum concentration monitoring to avoid toxicity.
Serum theophylline levels must be monitored to avoid toxicity; therapeutic range is 10-20 mcg/m L.,Risk of seizures and cardiac arrhythmias, especially at supratherapeutic levels.,Use with caution in patients with peptic ulcer disease, seizure disorders, cardiac arrhythmias, and hepatic impairment.,Numerous drug interactions due to CYP1A2 inhibition or induction (e.g., cimetidine, fluoroquinolones, smoking).
Narrow therapeutic index; monitor serum concentrations (target 10-20 mcg/m L); caution in patients with peptic ulcer, hyperthyroidism, seizure disorders, cardiac arrhythmias; use with drugs that affect CYP1A2 (e.g., cimetidine, fluoroquinolones, fluvoxamine) or induce metabolism (e.g., smoking, rifampin, phenytoin).
Hypersensitivity to theophylline or any component of the formulation.,Pre-existing cardiac arrhythmias (excluding bradyarrhythmias).,Active seizure disorder unless controlled with anticonvulsants.,Concurrent use with ephedrine or other sympathomimetics (relative).
Hypersensitivity to aminophylline, theophylline, or ethylenediamine; active peptic ulcer disease; uncontrolled seizure disorders; severe cardiac arrhythmias (unless patient is undergoing monitored treatment).
High-fat meals may increase absorption, but consistent timing with food is key. Avoid excessive caffeine intake. Charcoal-broiled foods may increase metabolism, reducing effectiveness.
High-fat meals can delay absorption of aminophylline. Avoid charred meat and foods containing large amounts of caffeine. Cruciferous vegetables (broccoli, brussels sprouts) may increase metabolism. Maintain consistent dietary intake of protein and carbohydrates as changes can affect theophylline clearance.
Theophylline (active ingredient of QUIBRON-T) is not considered a major teratogen. First trimester exposure is not associated with an increased risk of major congenital malformations based on population data. Second and third trimester use may be associated with transient neonatal effects such as irritability, jitteriness, tachycardia, and feeding intolerance due to transplacental passage. No specific structural teratogenicity has been established.
Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal asthma control benefits outweigh risks. Third trimester: Risk of neonatal apnea, irritability, and tachycardia if maternal levels are high; avoid toxic levels.
Theophylline is excreted into breast milk in small amounts (M/P ratio ~0.6-0.7). Milk levels are about 60-70% of maternal serum levels. Breastfeeding is generally considered acceptable, but monitor the infant for signs of theophylline toxicity (irritability, jitteriness, poor feeding). Caution is advised in preterm or medically fragile infants.
Aminophylline is excreted into breast milk; the M/P ratio (milk-to-plasma ratio) is approximately 0.6-0.8. Infant exposure is low (about 1-10% of maternal weight-adjusted dose). Use with caution; monitor infant for irritability and sleep disturbance. Generally considered compatible with breastfeeding.
Theophylline clearance is decreased in the third trimester due to reduced hepatic metabolism and increased volume of distribution. Dose requirements may need reduction by 20-30% in the third trimester, with close monitoring of serum levels to maintain therapeutic range. Postpartum, clearance returns to prepregnancy levels within 2-4 weeks, requiring dose readjustment upward.
Pregnancy reduces theophylline clearance by 30-50% due to decreased hepatic metabolism and increased volume of distribution. Dose adjustments may be needed: reduce dose by 30% in the third trimester or monitor serum concentrations closely to maintain therapeutic levels (5-15 mcg/m L). Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; readjust accordingly.
Quibron-T (theophylline) has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels due to variable metabolism. Cimetidine, ciprofloxacin, and fluvoxamine inhibit metabolism, increasing toxicity risk. Smoking and carbamazepine induce metabolism, reducing efficacy.
Aminophylline is a bronchodilator composed of theophylline and ethylenediamine. The ethylenediamine component can cause hypersensitivity reactions. Monitor theophylline serum levels (target 10-20 mcg/m L). Use with caution in patients with cardiac arrhythmias, seizures, or peptic ulcer disease. Avoid in patients with porphyria. Cimetidine, ciprofloxacin, and macrolides can increase theophylline levels. Smoking induces metabolism, requiring higher doses.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid caffeine-containing products (coffee, tea, cola) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, tachycardia, or seizures.,Do not smoke or stop smoking suddenly; notify your doctor if you do.,Keep regular appointments for blood level monitoring.
Take this medication exactly as prescribed, with or without food.,Do not crush or chew extended-release formulations.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate, energy drinks) as it may increase side effects.,Report symptoms such as rapid heart rate, persistent nausea/vomiting, insomnia, or seizures immediately.,Do not stop abruptly without consulting your doctor.,Keep a regular dosing schedule to maintain consistent blood levels.
No interactions on record
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUIBRON-T vs AMINOPHYLLIN, answered by our medical review team.
QUIBRON-T is a Xanthine Bronchodilator that works by Quibron-T (theophylline) inhibits phosphodiesterase, increasing intracellular c AMP in airway smooth muscle and inflammatory cells, leading to bronchodilation and anti-inflammatory effects. It also antagonizes adenosine receptors and enhances respiratory drive.. AMINOPHYLLIN is a Xanthine Bronchodilator that works by Non-selective phosphodiesterase inhibitor, increasing intracellular c AMP and c GMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUIBRON-T and AMINOPHYLLIN depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUIBRON-T is: Oral: 200-400 mg every 6-8 hours; sustained-release: 200-600 mg every 12 hours.. The standard adult dose of AMINOPHYLLIN is: Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUIBRON-T and AMINOPHYLLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUIBRON-T is classified as Category C. Theophylline (active ingredient of QUIBRON-T) is not considered a major teratogen. First trimester exposure is not associated with an increased risk of major congenital malformatio. AMINOPHYLLIN is classified as Category C. Aminophylline, a theophylline salt, is not teratogenic in humans. First trimester: No increased risk of major malformations. Second trimester: No specific fetal risks; maternal ast. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.